In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's Love Affair With Dealmaking: No End In Sight

Executive Summary

The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.

Advertisement

Related Content

Mylan Finally Nabs Meda In Diversification Play
Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers
Finding The Fit For Ophthalmology In The New Pfizer
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza
The Shrinking Value Of Best-In-Class And First-In-Class Drugs
Biosimilars: Improving Patient Access To Biologics While Bending The Cost Curve

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

IV004453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel